Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Triple Negative Breast Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Breast Cancer (2257
)
HER2 Negative Breast Cancer (484
)
HER2 Positive Breast Cancer (470
)
Hormone Receptor Positive Breast Cancer (317
)
Estrogen Receptor Positive Breast Cancer (213
)
Male Breast Cancer (10
)
Hormone Receptor Negative Breast Cancer (3
)
Breast Cancer (2257
)
HER2 Negative Breast Cancer (484
)
HER2 Positive Breast Cancer (470
)
Hormone Receptor Positive Breast Cancer (317
)
Estrogen Receptor Positive Breast Cancer (213
)
Male Breast Cancer (10
)
Hormone Receptor Negative Breast Cancer (3
)
›
Associations
(336)
News
Trials
VERI cancer hierarchy
x
x
x
x
Reset Filters
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
NPJ Breast Cancer - 3 weeks (New C3)
atezolizumab
Sensitive
:
A1
NPJ Breast Cancer - 3wk
atezolizumab
Sensitive: A1 - Approval
NPJ Breast Cancer - 3 weeks
atezolizumab
Sensitive
:
A1
NPJ Breast Cancer - 3 weeks - (New C3)
AR positive
Triple Negative Breast Cancer
AR positive
Triple Negative Breast Cancer
VNLG-152R
Sensitive: D – Preclinical
Front Oncol - 3 weeks (New D)
VNLG-152R
Sensitive
:
D
Front Oncol - 3wk
VNLG-152R
Sensitive: D – Preclinical
Front Oncol - 3 weeks
VNLG-152R
Sensitive
:
D
Front Oncol - 3 weeks - (New D)
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Triple Negative Breast Cancer
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
sacituzumab govitecan-hziy
Sensitive
:
A1
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
sacituzumab govitecan-hziy
Sensitive
:
A1
No biomarker
Triple Negative Breast Cancer
No biomarker
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Triple Negative Breast Cancer
No biomarker
Triple Negative Breast Cancer
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
pegylated liposomal doxorubicin
Sensitive
:
A2
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
pegylated liposomal doxorubicin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
pegylated liposomal doxorubicin
Sensitive
:
A2
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
pegylated liposomal doxorubicin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
talazoparib
Sensitive: A2 - Guideline
talazoparib
Sensitive
:
A2
talazoparib
Sensitive: A2 - Guideline
talazoparib
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
talazoparib
Sensitive: A2 - Guideline
talazoparib
Sensitive
:
A2
talazoparib
Sensitive: A2 - Guideline
talazoparib
Sensitive
:
A2
No biomarker
Triple Negative Breast Cancer
No biomarker
Triple Negative Breast Cancer
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
doxorubicin hydrochloride
Sensitive: A2 - Guideline
doxorubicin hydrochloride
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
Immunotherapy
Sensitive: A2 - Guideline
Immunotherapy
Sensitive
:
A2
Immunotherapy
Sensitive: A2 - Guideline
Immunotherapy
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
CaT
Sensitive: B - Late Trials
CaT
Sensitive
:
B
CaT
Sensitive: B - Late Trials
CaT
Sensitive
:
B
No biomarker
Triple Negative Breast Cancer
No biomarker
Triple Negative Breast Cancer
IPI-549
Sensitive: B - Late Trials
IPI-549
Sensitive
:
B
IPI-549
Sensitive: B - Late Trials
IPI-549
Sensitive
:
B
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login